Literature DB >> 1419603

Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates.

P E Pizao1, D M Lyaruu, G J Peters, J van Ark-Otte, B Winograd, G Giaccone, H M Pinedo.   

Abstract

This study assessed the growth pattern, cellular organisation and chemosensitivity of established human tumour cell lines growing as postconfluent cultures in 'V'-bottomed, 96-well microtiter plates. Cross-sections of the colon (HT29, SW620, SW1116), ovarian (A2780) and head and neck (UM-SCC-22B) carcinoma microcultures allowed in situ evaluation of the cellular organisation in the wells. After 5 days of growth, every cell line had reached confluence, but each of them displayed a specific pattern of cell stacking which ranged from two to ten layers. Postconfluent HT29 cells displayed morphologic features suggestive of some degree of enterocytic differentiation. Growth and cytotoxicity could be studied reliably and reproducibly in this system with the sulforhodamine B protein assay. Against HT29 postconfluent cultures, the EC50's (drug concentrations producing absorbance readings 50% lower than those of non-treated wells) of 5-fluorouracil and of the ether lipid, hexadecylphosphocholine, were 1 mM and 50 microM respectively. The possibility to perform chemosensitivity tests using semiautomated microtiter plate technology supports further evaluation of this system as an alternative antitumour drug testing model.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1419603      PMCID: PMC1977414          DOI: 10.1038/bjc.1992.333

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines.

Authors:  I Chantret; A Barbat; E Dussaulx; M G Brattain; A Zweibaum
Journal:  Cancer Res       Date:  1988-04-01       Impact factor: 12.701

2.  Relationship between extracellular matrix interactions and degree of differentiation in human colon carcinoma cell lines.

Authors:  G W Daneker; A J Piazza; G D Steele; A M Mercurio
Journal:  Cancer Res       Date:  1989-02-01       Impact factor: 12.701

3.  Comparative chemosensitivity of exponential- versus plateau-phase cells in both in vitro model systems.

Authors:  P R Twentyman
Journal:  Cancer Treat Rep       Date:  1976-12

4.  The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viability.

Authors:  Y Maehara; H Anai; R Tamada; K Sugimachi
Journal:  Eur J Cancer Clin Oncol       Date:  1987-03

5.  Postconfluency MDCK monolayers as an in vitro model of solid tumor chemosensitivity.

Authors:  P Skehan; J Thomas; S J Friedman
Journal:  Cell Biol Toxicol       Date:  1986-09       Impact factor: 6.691

6.  Effect of glutamine deprivation and glutamate or ammonium chloride addition on growth rate, metabolism and differentiation of human colon cancer cell-line HT29.

Authors:  V Viallard; C Denis; V Trocheris; J C Murat
Journal:  Int J Biochem       Date:  1986

7.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

8.  Increased growth adaptability to 5-fluorouracil and methotrexate of HT-29 sub-populations selected for their commitment to differentiation.

Authors:  T Lesuffleur; A Kornowski; C Augeron; E Dussaulx; A Barbat; C Laboisse; A Zweibaum
Journal:  Int J Cancer       Date:  1991-11-11       Impact factor: 7.396

9.  Monoclonal antibodies to human colorectal epithelium: markers for differentiation and tumour characterization.

Authors:  P I Richman; W F Bodmer
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

10.  Spontaneous and induced dome formation by two clonal cell populations derived from a human adenocarcinoma cell line, HT29.

Authors:  J Fantini; B Abadie; A Tirard; L Remy; J P Ripert; A el Battari; J Marvaldi
Journal:  J Cell Sci       Date:  1986-07       Impact factor: 5.285

View more
  8 in total

1.  Gompertzian growth pattern correlated with phenotypic organization of colon carcinoma, malignant glioma and non-small cell lung carcinoma cell lines.

Authors:  M A A Castro; F Klamt; V A Grieneisen; I Grivicich; J C F Moreira
Journal:  Cell Prolif       Date:  2003-04       Impact factor: 6.831

2.  Mdr1 transfection causes enhanced apoptosis by paclitaxel: an effect independent of drug efflux function of P-glycoprotein.

Authors:  D Li; J L Au
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

3.  Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents.

Authors:  Dong Li; Seong H Jang; Jonghan Kim; M Guillaume Wientjes; Jessie L S Au
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

4.  Expression of CDX2 in normal and neoplastic human colon tissue and during differentiation of an in vitro model system.

Authors:  D Qualtrough; T Hinoi; E Fearon; C Paraskeva
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

5.  Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.

Authors:  M J Welters; A M Fichtinger-Schepman; R A Baan; A J Jacobs-Bergmans; A Kegel; W J van der Vijgh; B J Braakhuis
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

6.  Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.

Authors:  Auke D Adema; Karijn Floor; Kees Smid; Richard J Honeywell; George L Scheffer; Gerrit Jansen; Godefridus J Peters
Journal:  Springerplus       Date:  2014-12-13

7.  Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.

Authors:  Maryam Zanjirband; Richard J Edmondson; John Lunec
Journal:  Oncotarget       Date:  2016-06-28

8.  Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.

Authors:  Maryam Zanjirband; Nicola Curtin; Richard J Edmondson; John Lunec
Journal:  Oncotarget       Date:  2017-07-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.